Olopatadine
PATANOL
What it isTopical H1 antagonist with mast-cell stabilization; allergic conjunctivitis and rhinitis.
Why this oneAvailability as both eye drops and nasal spray distinguishes it from most dual-action topical antihistamines.
What limits itLocal irritation and bitter taste intranasally are the main drawbacks; systemic effects are minimal.
FDA-approved for
- allergic conjunctivitis (1996)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Ocular itch due to allergic conjunctivitis (OTC) | Adults & children ≥2 yr | 1 drop in affected eye(s) QD | 1 drop QD | 1 drop per eye per day |
Renal Undefined
Hepatic Undefined
Instructions
- For ophthalmic use only
- Do not use more than 1 drop per eye per day
- If using other eye drops, wait at least 5 minutes between products
- Replace cap after each use
- Children under 2 years: consult a doctor
Pregnancy Undefined
Lactation Undefined
NO BOXED WARNINGS
Principal riskLocal irritation; bitter taste intranasally
Cost, est. cash$10–$400/month
Generic entry2014
Classes and tags
Clinical profile
Legacy pregnancy categoryC
Defining liabilityLocal irritation, sensitization or administration-site injury; negligible systemic toxicity at usual use.
Mechanism of action: Olopatadine ballicule
Open Olopatadine in the interactive console ↗
Memory aids: mascots and interaction avatars
